Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
By Linda Brandt Myers – Patient ITHACA, N.Y. In May 1994, on the eve of my marriage to my husband, Sandy, I was diagnosed with chronic lymphocytic leukemia (CLL). I remember
A video interview between Terry Evans, CLL patient and Sheila Hoff, RN, Clinical Trial Nurse at the University of California, San Diego, Moores Cancer Center. (See video at the bottom of
Though it is still very early on, BTK degrader BGB-16673 appears tolerable. Clinical trials of BTK degraders may be especially of interest to CLL patients
Dr. Susan O’Brien eloquently addressed the issue of equipoise in clinical trials for CLL / SLL a full 10 years ago.
In partnership with Huntsman Cancer Institute (HCI), CLL Society invites you to attend our virtual Ed Forum focused on chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL / SLL). Featured speakers will present the basics of CLL / SLL diagnosis, testing, early management, the importance of secondary cancer screenings, vaccination information, and staying health through diet and exercise. Speakers will also provide an overview of CLL treatment options and clinical trials, as well as strategies to becoming an effective self-advocate from the patient perspective.
I had always thought that a cancer support group was probably useful for some, but definitely not for me. Since my diagnoses of CLL / SLL about 11 years ago, my sole interest has been in getting information, current trends in treatment, potential new drugs, clinical trials, and trial results.
Cellular therapies are a special type of immunotherapy that use cells, a “living drug”, to treat CLL / SLL. CAR-T is a revolutionary therapy in CLL and other blood cancers, which is currently available through clinical trials. Learn more about this “living drug” and other cellular therapy options for CLL patients with Dr. Mazyar Shadman.
In partnership with Huntsman Cancer Institute (HCI), CLL Society invites you to attend our virtual Ed Forum focused on chronic lymphocytic leukemia (CLL). Featured speakers will present the basics of CLL diagnosis, early management, clinical trials, treatment options, COVID-19 considerations for CLL patients, patient perspectives, and strategies to become an effective self-advocate.
At the annual meeting of the American Society of Hematology (ASH) 2020, our own Dr. Brian Koffman interviewed Dr. Lindsey Roeker, a hematologic oncologist at Memorial Sloan Kettering Cancer Center. They discussed epcoritamab, a new bispecific antibody, that is currently being tested in clinical trials.
One click to our most popular content.
